Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 134, Issue 12, Pages 2772-2777
Publisher
Wiley
Online
2013-10-12
DOI
10.1002/ijc.28503
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients
- (2013) M Pichler et al. BRITISH JOURNAL OF CANCER
- Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma
- (2013) M Santoni et al. BRITISH JOURNAL OF CANCER
- Sorafenib induces autophagy and suppresses activation of human macrophage
- (2013) Jiunn-Chang Lin et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Regulation of Immune Responses by mTOR
- (2012) Jonathan D. Powell et al. Annual Review of Immunology
- Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model
- (2012) Shuning He et al. JOURNAL OF PATHOLOGY
- Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression
- (2012) M A López-Lago et al. ONCOGENE
- Intratumoral alterations of dendritic-cell differentiation and CD8+T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma
- (2012) Elfriede Noessner et al. OncoImmunology
- Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
- (2011) Charlotte M Huijts et al. BMC CANCER
- Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC)
- (2011) Chenghai Li et al. CANCER BIOLOGY & THERAPY
- Tumor-Associated Macrophages Mediate Immunosuppression in the Renal Cancer Microenvironment by Activating the 15-Lipoxygenase-2 Pathway
- (2011) I. Daurkin et al. CANCER RESEARCH
- The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma
- (2011) Daniel Keizman et al. EUROPEAN JOURNAL OF CANCER
- T Lymphocyte Recruitment into Renal Cell Carcinoma Tissue: A Role for Chemokine Receptors CXCR3, CXCR6, CCR5, and CCR6
- (2011) Kimberley A. Oldham et al. EUROPEAN UROLOGY
- MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
- (2011) James Finke et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging
- (2011) Judith Eckl et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Followup of Neutrophil-to-Lymphocyte Ratio and Recurrence of Clear Cell Renal Cell Carcinoma
- (2011) Yoshio Ohno et al. JOURNAL OF UROLOGY
- The Effect of Sunitinib on Immune Subsets in Metastatic Clear Cell Renal Cancer
- (2011) Thomas Powles et al. UROLOGIA INTERNATIONALIS
- Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
- (2010) S. Patil et al. ANNALS OF ONCOLOGY
- Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained
- (2010) Jennifer S. Ko et al. CANCER RESEARCH
- Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects
- (2010) W. Zhang et al. CLINICAL CANCER RESEARCH
- The multikinase inhibitor Sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE2 in murine macrophages
- (2010) Justin P. Edwards et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients
- (2010) Ingrid M.E. Desar et al. INTERNATIONAL JOURNAL OF CANCER
- Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2
- (2010) Yuxian Huang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients
- (2010) Olivier Adotevi et al. JOURNAL OF IMMUNOTHERAPY
- Pretreatment Neutrophil-to-Lymphocyte Ratio as an Independent Predictor of Recurrence in Patients With Nonmetastatic Renal Cell Carcinoma
- (2010) Yoshio Ohno et al. JOURNAL OF UROLOGY
- Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array
- (2009) J L Perez-Gracia et al. BRITISH JOURNAL OF CANCER
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
- (2009) R Kumar et al. BRITISH JOURNAL OF CANCER
- Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
- (2009) C Alfaro et al. BRITISH JOURNAL OF CANCER
- Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice
- (2009) Yanhong Gu et al. CLINICAL IMMUNOLOGY
- Angiogenesis in renal cell carcinoma: The role of tumor-associated macrophages
- (2009) Hiroshi Toge et al. INTERNATIONAL JOURNAL OF UROLOGY
- Presence of Intratumoral Neutrophils Is an Independent Prognostic Factor in Localized Renal Cell Carcinoma
- (2009) Hanne Krogh Jensen et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro
- (2009) M. Krusch et al. JOURNAL OF IMMUNOLOGY
- Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
- (2008) M. M. Hipp et al. BLOOD
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
- (2008) J. H. Finke et al. CLINICAL CANCER RESEARCH
- Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation
- (2008) W Zhao et al. LEUKEMIA
- VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma
- (2007) Jacqueline Rivet et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started